INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

	March 31, 2023								December 31, 2022
(in millions)	Gross  Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross  Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(6,525)	$	—	$	4,195	$	10,720	$	(6,350)	$	—	$	4,370
Intangible asset – axicabtagene ciloleucel	7,110		(2,009)		—		5,101		7,110		(1,908)		—		5,202
Intangible asset – Trodelvy(1)	11,730		(1,192)		—		10,538		5,630		(973)		—		4,657
Intangible asset – Hepcludex	845		(179)		—		666		845		(158)		—		687
Other	1,489		(762)		1		728		1,489		(733)		1		758
Total finite-lived assets	31,894		(10,667)		1		21,228		25,794		(10,121)		1		15,674
Indefinite-lived assets – IPR&D(1)	7,120		—		—		7,120		13,220		—		—		13,220
Total intangible assets	$	39,014	$	(10,667)	$	1	$	28,348	$	39,014	$	(10,121)	$	1	$	28,894

_______________________________

(1)     In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.

Summary of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

	March 31, 2023								December 31, 2022
(in millions)	Gross  Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross  Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(6,525)	$	—	$	4,195	$	10,720	$	(6,350)	$	—	$	4,370
Intangible asset – axicabtagene ciloleucel	7,110		(2,009)		—		5,101		7,110		(1,908)		—		5,202
Intangible asset – Trodelvy(1)	11,730		(1,192)		—		10,538		5,630		(973)		—		4,657
Intangible asset – Hepcludex	845		(179)		—		666		845		(158)		—		687
Other	1,489		(762)		1		728		1,489		(733)		1		758
Total finite-lived assets	31,894		(10,667)		1		21,228		25,794		(10,121)		1		15,674
Indefinite-lived assets – IPR&D(1)	7,120		—		—		7,120		13,220		—		—		13,220
Total intangible assets	$	39,014	$	(10,667)	$	1	$	28,348	$	39,014	$	(10,121)	$	1	$	28,894

_______________________________

(1)     In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.

Summary of Estimated Future Amortization Expense

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March 31, 2023:

(in millions)	Amount
2023 (remaining nine months)	$	1,794
2024	2,392
2025	2,386
2026	2,378
2027	2,378
Thereafter	9,900
Total	$	21,228